We've found
10,036 Brain Cancer
clinical trials
Brain Metastases From Non-small Cell Lung Cancer (NSCLC) Clinical Trial
Effect of TTFields (150 kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-10 Brain Metastases Following Radiosurgery (METIS)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neuroblastoma Clinical Trial
Neuroblastoma Maintenance Therapy Trial
Status: Enrolling,
Phase
II
Updated: 2/13/2018
Click here to add this to my saved trials
Oncology Clinical Trial
Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Glioblastoma Clinical Trial
Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Glioblastoma Clinical Trial
Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Neuroendocrine Tumors Clinical Trial
A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
HeadStart4: Newly Diagnosed Children (
Status: Enrolling,
Phase
IV
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
HeadStart4: Newly Diagnosed Children (
Status: Enrolling,
Phase
IV
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Brain Tumor Clinical Trial
The Purpose of This Study is to Test Any Good and Bad Effects of a Study Drug Called Abemaciclib (LY2835219) in Patients With Recurrent Brain Tumors.
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Brain Tumor Clinical Trial
The Purpose of This Study is to Test Any Good and Bad Effects of a Study Drug Called Abemaciclib (LY2835219) in Patients With Recurrent Brain Tumors.
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Glioblastoma Clinical Trial
Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Glioblastoma Clinical Trial
A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Glioblastoma Clinical Trial
A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Glioblastoma Clinical Trial
A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology, Reproductive Clinical Trial
QUILT-3.055: A Study of ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor in Patients With Advanced Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology, Reproductive Clinical Trial
QUILT-3.055: A Study of ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor in Patients With Advanced Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
We've found
10,036 Brain Cancer
clinical trials
Brain Metastases From Non-small Cell Lung Cancer (NSCLC) Clinical Trial
Updated: 12/31/1969
Effect of TTFields (150 kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-10 Brain Metastases Following Radiosurgery (METIS)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Updated: 12/31/1969
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Updated: 12/31/1969
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Updated: 12/31/1969
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Updated: 12/31/1969
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Neuroblastoma Clinical Trial
Updated: 2/13/2018
Neuroblastoma Maintenance Therapy Trial
Status: Enrolling,
Phase
II
Updated: 2/13/2018
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Glioblastoma Clinical Trial
Updated: 12/31/1969
Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Glioblastoma Clinical Trial
Updated: 12/31/1969
Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Neuroendocrine Tumors Clinical Trial
Updated: 12/31/1969
A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
HeadStart4: Newly Diagnosed Children (
Status: Enrolling,
Phase
IV
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
HeadStart4: Newly Diagnosed Children (
Status: Enrolling,
Phase
IV
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Brain Tumor Clinical Trial
Updated: 12/31/1969
The Purpose of This Study is to Test Any Good and Bad Effects of a Study Drug Called Abemaciclib (LY2835219) in Patients With Recurrent Brain Tumors.
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Brain Tumor Clinical Trial
Updated: 12/31/1969
The Purpose of This Study is to Test Any Good and Bad Effects of a Study Drug Called Abemaciclib (LY2835219) in Patients With Recurrent Brain Tumors.
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Updated: 12/31/1969
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Glioblastoma Clinical Trial
Updated: 12/31/1969
Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Glioblastoma Clinical Trial
Updated: 12/31/1969
A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Glioblastoma Clinical Trial
Updated: 12/31/1969
A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Glioblastoma Clinical Trial
Updated: 12/31/1969
A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology, Reproductive Clinical Trial
Updated: 12/31/1969
QUILT-3.055: A Study of ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor in Patients With Advanced Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology, Reproductive Clinical Trial
Updated: 12/31/1969
QUILT-3.055: A Study of ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor in Patients With Advanced Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials